Gingivitis, Halitosis, Periodontal Diseases, Periodontitis
Conditions
Keywords
Gingivitis, Periodontal disease, Inflammation, Teeth whitening, Breath freshening, Periodontal pathogens, Bleeding on probing
Brief summary
The purpose of this study is to evaluate the safety and efficacy of a newly formulated foaming gel product on gingivitis and/or moderate periodontitis when used with or without the GLO Science accelerating device (GLO Device), compared to standard tooth brushing with antioxidant whitening toothpaste with or without flossing (split mouth design for control group). This is a 60-day randomized single blinded parallel group study. After 42 days, all use of interventional products were discontinued, and the participants returned to the clinical center at day 60 for final measurements. The primary outcomes assessed in this study were the differences in gingival index (GI) and bleeding on probing (BOP) from baseline to 42 & 60 days. The secondary outcomes are tooth whitening, oral malodor, pocket depth and plaque amount. It is hypothesized that participants using the gingival health product with the GLO Device will experience greater reductions in GI & BOP measurements than the control group, as well as participants using the gingival health product on a toothbrush alone.
Interventions
OTHERGingival health formulation in an accelerating device
The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
OTHERGingival health formulation on a toothbrush
The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
OTHEROTC fluoride toothpaste
OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
Sponsors
The Forsyth Institute
Glo Science, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Willing and able to read, understand and sign an Informed Consent Form * Good general health as evidenced by the medical history * Between 18 and 55 years of age * Male or female * Minimum of 20 teeth, excluding crowns and third molar teeth * Mean whole mouth Gingival Index \>/=2.0 at baseline; sites with \</=7mm pocket depth * Willing to abstain from all oral hygiene procedures 12-18 hours prior to clinical visits * Willing to abstain from eating and drinking for 2 hours prior to clinical visits, only drinking water is allowed * Willing to abstain from chewing gums, oral whitening products, mouthwashes and tobacco products for the study duration * Able to understand and follow study directions
Exclusion criteria
* Chronic use of photosensitizing medications including NSAIDs, antidepressants, antibiotics and beta-blockers * Diagnosed with diabetes * Presence of orthodontic appliances * Presence of large restorations, crown or veneer at the anterior of both upper and lower teeth (including premolar teeth) * A soft or hard tissue tumor of the oral cavity * Carious lesions requiring immediate treatment * Patients with severe internal (tetracycline stains) and external discoloration (fluorosis) * Patients with severe chronic periodontitis, aggressive periodontitis, acute necrotizing ulcerative gingivitis, or generalized gingival recession \>2mm as evidenced by clinical oral exam * Pregnant or breast-feeding women * Allergy to home bleaching products such as hydrogen peroxide and carbide peroxide * Use of antibiotics within 3 months of enrollment * History of drug use that is associated with gum overgrowth (i.e., Dilantin, nifedipine, etc.) * Chronic use of medication such as steroids, anti-coagulant medications, immunosuppressant medication or any other medications or medical conditions that in the opinion of the Investigator would interfere with the evaluation or confound interpretation of the study results. Use of low dose of ASA (\<325mg) is permitted. * Medical condition which requires pre-medication prior to dental visits/procedures * Current smoking and former smoking within one year of enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in bleeding on probing | Baseline to 42 days |
| Differences in Gingival Index | Baseline to 42 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in oral malodor | Baseline to 42 days | Chromatographic measure of volatile sulfur compounds (hydrogen sulfide, dimethyl sulfide, methyl mercaptan) |
| Change in tooth whitening | Baseline to 42 days | — |
| Difference in Plaque Index | Baseline to 42 days | — |
| Change in inflammatory cytokines | Baseline to 28 days | Measurement of IL-1B, TNF-a, IL-6, IL-8 & MCP-1 volume from gingival crevicular fluid samples |
| Change in sub-gingival bacterial profile | Baseline to 28 days | DNA-DNA Hybridization Checkerboard; Measurement of bacterial load |
| Difference in mean probing depth | Baseline to 42 days | — |
Countries
United States
Outcome results
None listed